The fact that HIV infection can be efficiently suppressed by EFdA and that this suppression is accompanied by human CD4+ T cell recovery have broad implications for the adjustment of human dosing regimens to improve EFdA safety. This evidence concerns the gene CD4 and HIV infectious disease.